Taysha Gene Therapies (NASDAQ:TSHA) Posts Quarterly Earnings Results, Misses Estimates By $0.02 EPS

Key Points

• Taysha Gene Therapies reported a quarterly loss of $0.13 per share, missing analyst expectations by $0.02. Despite the earnings miss, shares rose 5.3% to $6.71.
• The company’s stock is supported by strong liquidity, with current and quick ratios of 14.04, while institutional investors own 77.70% of outstanding shares.
• Analyst sentiment remains generally positive, with an average “Buy” rating and a $12.77 price target, although some firms maintain “Sell” ratings. Goldman Sachs recently raised its target to $13.00.

Taysha Gene Therapies (NASDAQ:TSHA - Get Free Report) announced its earnings results on Tuesday. The company reported ($0.13) earnings per share for the quarter, missing the consensus estimate of ($0.11) by ($0.02), Zacks reports.

Taysha Gene Therapies Stock Up 5.3%

NASDAQ TSHA traded up $0.34 during trading hours on Tuesday, reaching $6.71. 2,906,729 shares of the company traded hands, compared to its average volume of 2,868,341. The stock has a market capitalization of $1.93 billion, a PE ratio of -17.65 and a beta of 1.22. The company has a current ratio of 14.04, a quick ratio of 14.04 and a debt-to-equity ratio of 0.23. Taysha Gene Therapies has a 12 month low of $2.69 and a 12 month high of $7.30. The company has a 50 day moving average of $6.06 and a two-hundred day moving average of $5.45.

Insider Buying and Selling at Taysha Gene Therapies

In other news, insider Sukumar Nagendran sold 200,000 shares of the company's stock in a transaction dated Friday, July 10th. The shares were sold at an average price of $6.24, for a total value of $1,248,000.00. Following the sale, the insider owned 936,410 shares in the company, valued at approximately $5,843,198.40. This represents a 17.60% decrease in their position. The sale was disclosed in a document filed with the SEC, which can be accessed through this hyperlink. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Insiders own 3.48% of the company's stock.

Institutional Trading of Taysha Gene Therapies

Several hedge funds and other institutional investors have recently bought and sold shares of the company. Marex Group plc bought a new position in Taysha Gene Therapies during the 2nd quarter worth approximately $29,000. E Fund Management Co. Ltd. acquired a new stake in shares of Taysha Gene Therapies during the 2nd quarter valued at approximately $31,000. Tower Research Capital LLC TRC raised its position in shares of Taysha Gene Therapies by 156.5% during the 2nd quarter. Tower Research Capital LLC TRC now owns 17,606 shares of the company's stock valued at $41,000 after acquiring an additional 10,742 shares in the last quarter. BNP Paribas Financial Markets lifted its stake in Taysha Gene Therapies by 51.9% during the second quarter. BNP Paribas Financial Markets now owns 18,591 shares of the company's stock worth $43,000 after purchasing an additional 6,350 shares during the last quarter. Finally, Caitong International Asset Management Co. Ltd lifted its stake in Taysha Gene Therapies by 143.8% during the fourth quarter. Caitong International Asset Management Co. Ltd now owns 7,811 shares of the company's stock worth $43,000 after purchasing an additional 4,607 shares during the last quarter. 77.70% of the stock is owned by institutional investors.

Analyst Ratings Changes

A number of equities analysts have commented on TSHA shares. Weiss Ratings reiterated a "sell (d-)" rating on shares of Taysha Gene Therapies in a report on Wednesday, June 24th. Wall Street Zen downgraded Taysha Gene Therapies from a "hold" rating to a "sell" rating in a research note on Saturday, May 9th. The Goldman Sachs Group lifted their target price on Taysha Gene Therapies from $11.00 to $13.00 and gave the stock a "buy" rating in a research report on Tuesday, July 21st. Citigroup reissued an "outperform" rating on shares of Taysha Gene Therapies in a report on Tuesday, June 23rd. Finally, Needham & Company LLC restated a "buy" rating and set a $12.00 price objective on shares of Taysha Gene Therapies in a research note on Tuesday, June 30th. Two investment analysts have rated the stock with a Strong Buy rating, eleven have assigned a Buy rating and one has assigned a Sell rating to the company's stock. According to data from MarketBeat, Taysha Gene Therapies presently has an average rating of "Buy" and an average target price of $12.77.

About Taysha Gene Therapies

Taysha Gene Therapies, Inc NASDAQ: TSHA is a clinical-stage biotechnology company focused on developing gene therapies for rare monogenic diseases of the central nervous system. Using a proprietary adeno-associated viral (AAV) vector platform, the company engineers novel capsids and regulatory elements to optimize delivery and expression of therapeutic genes. Its pipeline features lead programs such as TSHA-102 for GM2 gangliosidoses (Tay–Sachs and Sandhoff diseases), TSHA-101 for GM1 gangliosidosis and TSHA-103 for aromatic l-amino acid decarboxylase (AADC) deficiency, alongside earlier-stage candidates targeting other life-threatening pediatric CNS disorders.

Founded in 2019 and headquartered in Dallas, Texas, Taysha Gene Therapies completed its initial public offering in May 2021.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.

Continue following MarketBeat

Add MarketBeat as your preferred source on Google to see our latest stories in your feed.

Add As Preferred Source